These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 30371575)

  • 21. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
    Schlüter B; Bohuslavizki KH; Beyer W; Plotkin M; Buchert R; Clausen M
    J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
    Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
    Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The early detection of metastatic differentiated thyroid cancer using 131I total body scan and treatment with 131I].
    Ikekubo K; Hino M; Ito H; Yamaguchi H; Saiki Y; Ui K; Tominaga E; Nakanishi M; Kawai J; Koh T
    Kaku Igaku; 1991 Mar; 28(3):247-59. PubMed ID: 1904509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT.
    Wong KK; Sisson JC; Koral KF; Frey KA; Avram AM
    AJR Am J Roentgenol; 2010 Sep; 195(3):730-6. PubMed ID: 20729453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
    Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
    Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ
    Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K; Pipatrattana R; Tepmongkol S; Sirisalipoch S; Chaiwatanarat T
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
    Ng DC; Sundram FX; Sin AE
    J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.
    Grewal RK; Tuttle RM; Fox J; Borkar S; Chou JF; Gonen M; Strauss HW; Larson SM; Schöder H
    J Nucl Med; 2010 Sep; 51(9):1361-7. PubMed ID: 20720058
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients.
    Pace L; Klain M; Salvatore B; Nicolai E; Zampella E; Assante R; Pellegrino T; Storto G; Fonti R; Salvatore M
    Clin Nucl Med; 2015 Feb; 40(2):111-5. PubMed ID: 25546215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
    Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
    J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
    Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal in the identification of metastasis in differentiated thyroid cancer with 131I planar whole-body imaging and 124I PET.
    Van Nostrand D; Khorjekar GR; O'Neil J; Moreau S; Atkins FB; Kharazi P; Mete M; Chennupati SP; Burman KD; Wartofsky L
    J Nucl Med; 2012 Mar; 53(3):359-62. PubMed ID: 22315442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
    Pacini F; Capezzone M; Elisei R; Ceccarelli C; Taddei D; Pinchera A
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1499-501. PubMed ID: 11932271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation.
    Schmidt D; Szikszai A; Linke R; Bautz W; Kuwert T
    J Nucl Med; 2009 Jan; 50(1):18-23. PubMed ID: 19091884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
    Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of thyroid-stimulating hormone in 68Ga-DOTATATE PET/CT of radioiodine-refractory thyroid carcinoma: a pilot study.
    Almeida LS; Araújo MC; Zantut-Wittmann DE; Assumpção LV; Souza TF; Silva CM; Argenton JL; Santos AO; Mengatti J; Ramos CD; Etchebehere EC
    Nucl Med Commun; 2018 May; 39(5):441-450. PubMed ID: 29543624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.